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1. Introduction
Type 1 diabetes mellitus (T1DM) is a chronically progressive autoimmune disease that affects
approximately 1% of the population in the developed world. This adverse immune response
is induced and promoted by the interaction of both genetic and environmental factors. In
contrast, in type 2 diabetes mellitus (T2DM), insulin-resistance coupled with reduced insulin
output appears to be the major cause of hyperglycaemia (affecting approximately 6% of the
population). Although the aetiology of diabetes may differ from T1DM to T2DM, a common
feature associated with both types is the failure of pancreatic β-cells in the islets of Langerhans,
thus causing a reduction in insulin secretion, cell mass and ultimately apoptotic death.
However, the impact and time-course of pancreatic β-cell death, which may appear very
different in T1 and T2DM, may be related through common molecular mechanisms.
Glucose-stimulated insulin secretion (GSIS) is central to the physiological control of metabolic
fuel homeostasis, and its impairment is a hallmark of pancreatic β-cell failure in T2DM. β-Cells
are often referred to as "fuel sensors" as they continually monitor and respond to dietary
nutrients, under the modulation of additional neuro-hormonal and immunological signals, in
order to secrete insulin to best meet the needs of the organism. Therefore, β-cell dysfunction
and death in diabetes leads to hyperglycaemia and its complications. An intriguing charac‐
teristic of the pancreatic β-cells is their similarity to immune cells: 1) they can release cytokines;
2) they strongly respond to cytokines from other cells and tissues; 3) their function is dependent
on the production of reactive oxygen (ROS) and nitrogen species (RNS); 4) they express high
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levels of pro-inflammatory proteins such as nuclear transcription factor κB (NFκB), inducible
nitric oxide synthase (iNOS), NADPH oxidase (NOX), Toll-like receptors (TLR) and other
proteins in response to immune signals, but also to metabolic challenge. However and in
contrast to professional immunoinflammatory cells, such as macrophages or neutrophils, the
β-cell is fragile when subjected to immune attack and is highly vulnerable to oxidative stress.
In this chapter, we intend to review the mechanisms of insulin secretion in response to a wide
variety of metabolic stimuli, the ‘immune-like’ characteristics of the pancreatic β-cells with
respect to metabolism, secretion and cell defence, the similarities between β-cell failure/death
in T1DM and T2DM and finally, to suggest novel targets for the treatment of diabetes.
2. Regulation of β-cell function and insulin secretion
Control of energy metabolism is essential in maintaining cellular homeostasis in all animals
across the metazoan (all animals with differentiated tissues). Insulin and glucagon are
hormones produced by vertebrate organisms to regulate glycaemic homeostasis. In addition,
insulin-like and glucagon-like peptide genes have been detected in invertebrate organisms
including, insects, molluscs and nematodes, thus inferring a similar metabolic control that is
conserved among most species [1,2]. However, in the case of vertebrates, insulin and glucagon
are produced by cells located in the islets of Langerhans of the animal pancreas. Under normal
physiological conditions, blood glucose concentration is maintained within narrow limits by
an alternate release of these powerful proteins, regardless of nutrient intake or expenditure
(e.g. exercise). There are four main cell types that contribute to the regulation of this pancreatic
function and they include, α-cells, β-cells, δ-cells and pancreatic peptide (PP)-cells [3]. The role
of α-cells is to synthesise and secrete glucagon in response to low extracellular glucose
concentrations, thus replenishing the plasma carbohydrate level [3]. δ-Cells secrete somatos‐
tatin that has an inhibitory effect on insulin and glucagon release, while PP-cells secrete
pancreatic peptide whose physiological function has not been fully elucidated [3]. Conversely,
the function of β-cells has been extensively studied and they are responsible for the biosyn‐
thesis and release of insulin in response to elevated plasma glucose, amino acid and saturated
fatty acid levels [3]. These cells represent the most abundant cell type in pancreatic islets and
are the primary source of dysfunction in DM.
β-Cell responsiveness and subsequent insulin secretion is subject to a plethora of cellular
regulatory mechanisms. Insulin biosynthesis and secretion is a highly controlled system that
has many influencing extracellular and intracellular factors including, glucose, fatty acids,
amino acids, nucleotides, calcium/potassium electrochemical gradient, metabolic coupling
factors (MCFs), and level of ROS and RNS. Furthermore, the fact that cellular insulin secretion
is achieved by the physical release of vesicles or granules containing the protein, suggests that
the process acquires a greater degree of complexity and control, and is subject to vesicle
manufacture, recruitment and finally plasma membrane docking.
Glucose-Stimulated Insulin Secretion (GSIS) is fundamental to insulin exocytosis as glucose is
the most potent insulin secretagogue [4]. In an environment of excess extracellular glucose,
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β-cell plasma membrane transporter proteins GLUT1 and GLUT2, actively transport free
glucose molecules inside the cell where glycolysis can be initiated to create the nucleotide ATP
(Fig. 1). Consequently, intracellular metabolism of glucose by glycolysis, and further metab‐
olism of pyruvate via the downstream tricarboxylic acid (TCA) cycle, leads to elevated NADH,
FADH2 and ultimately ATP levels [4]. The increased intracellular ATP:ADP ratio closes
membrane-bound ATP-sensitive K+ channels, resulting in plasma membrane depolarisation
and a subsequent opening of membrane-bound voltage activated Ca2+ channels. A rapid influx
of calcium ions is promoted, causing the exocytosis of insulin through fusion of the insulin
containing vesicles with the plasma membrane via VAMP (vesicle-associated membrane
protein) and SNARE (soluble NH2-ethylmaleimide-sensitive fusion protein attachment
protein receptor) association [5]. This specific process of insulin secretion is known as KATP-
dependent GSIS, and since ATP generation is critical, the metabolic control points of glycolysis,
the TCA cycle and oxidative phosphorylation (i.e. activity of metabolic enzymes such as
hexokinase, phosphofructokinase, pyruvate kinase, pyruvate dehydrogenase, pyruvate
carboxylase, glutamate dehydrogenase and mitochondrial redox-shuttles) have a significant
impact on regulation of insulin release.
Figure 1. Mechanisms of nutrient and amino acid stimulated insulin secretion. Glucose metabolism is essential for
stimulation of insulin secretion. The mechanisms by which amino acids enhance insulin secretion are understood to
primarily rely on (a) direct depolarization of the plasma membrane (e.g. cationic amino acid, L-arginine); (b) metabo‐
lism (e.g. alanine, glutamine, leucine); and (c) co-transport with Na+ and cell membrane depolarization (e.g. alanine).
Notably, rapid partial oxidation may also initially increase both the cellular content of ATP (impacting on K+ATP chan‐
nel closure prompting membrane depolarization) and other stimulus secretion coupling factors. In the absence of glu‐
cose, fatty acids may be metabolised to generate ATP and maintain basal levels of insulin secretion. Adapted from [3].
However, there also remains the possibility that KATP-independent GSIS can occur in the β-
cell, although the exact methodology is still not fully understood. KATP-independent GSIS has
been illustrated in studies utilising diazoxide to maintain K+ channels in the open position [6]
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and in mice with disrupted/deleted K+ channels [7, 8]. GSIS was subsequently shown to be
possible in a KATP-independent manner and it is believed that these two co-ordinate mecha‐
nisms of insulin secretion (i.e. KATP-dependent & KATP-independent GSIS), are responsible for
the bi-phasic insulin response in animals. It is thought that the initial rise in insulin secretion
is KATP-dependent, while the second phase is mediated through KATP-independent interactions
dependent on mitochondrial activity [4,9].
Mitochondrial, lipid and amino acid metabolism plays a significant role in regulation of insulin
secretion and GSIS. Lipid and amino acid metabolites can generate, or can directly become
MCFs that enhance or inhibit GSIS. While individual amino acids alone at physiological
concentrations do not enhance GSIS, some specific amino acids at higher concentrations, or in
combination with others, can cause increments in GSIS [10]. Arginine, alanine, leucine and
glutamine can increase GSIS, while homocysteine and cysteine at elevated concentration can
inhibit GSIS [10]. The effect of amino acids is also dependent on whether β-cells are exposed
acutely or chronically, as chronic exposure may influence the expression of genes involved in
the control of insulin secretion [10,11]. In addition, another nutrient source, fatty acids, can
also regulate GSIS in both a positive or negative manner depending on the level of saturation,
carbon chain length, and whether exposure is under acute or chronic conditions. Saturated
fatty acids like palmitic and stearic acid are known to chronically decrease GSIS in vitro, but
palmitic acid can acutely enhance GSIS [12-14]. Conversely, chronic exposure to monounsa‐
turated oleic acid and polyunsaturated arachidonic acid can increase insulin production in β-
cells [13,15]. Fatty acids can amplify β-cell GSIS, and it is likely that they elevate insulin levels
by causing changes in calcium influx and proteins associated with ion channel activity [16].
Mitochondrial metabolism of amino and fatty acid is at the hub of the reported effects on
insulin secretion and GSIS, mainly because TCA-mediated metabolism of both leads to
increased ATP production and protein biosynthesis, which is a prerequisite for insulin
secretion (Fig. 1). The intricacies of mitochondrial-mediated metabolism of amino and fatty
acids will be discussed below.
3. Pancreatic β-cell metabolism and influencing factors
Pancreatic β-cells are unique and can be distinguished from other cell types by their metabolic
profile.  Several  key  characteristics  of  β-cells  include  the  ability  to  utilise  glucose  in  the
physiological range of 2-20mmol/L, express low levels of lactate dehydrogenase (LDH) and
plasma membrane monocarboxylate pyruvate/lactate transporter, have a corresponding high
activity of glycerol-3-phosphate and malate/aspartate redox shuttles, and finally possess an
elevated level of pyruvate dehydrogenase (PDH) and pyruvate carboxylase (PC) activity,
ensuring that both oxidative and anaplerotic metabolism of glucose and pyruvate can occur
preferentially in the near absence of lactate generation (Fig. 2) (further details can be found
in [4,10,11,17-21]). These adaptions are designed to specifically accelerate oxidative phosphor‐
ylation  and TCA activity  as  a  means  to  increase  ATP output  and consequently  insulin
exocytosis.
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Figure 2. Schematic diagram representing the metabolism of selected amino acids, highlighting related metabolic
stimulus-secretion coupling factors involved in insulin release. The pathway of glutamine metabolism via glutaminase,
GDH, and entry into the TCA cycle (glutaminolysis) is shown along with key points of amino acid interaction with glu‐
tamine and glucose metabolism. KG, -ketoglutarate; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
AT, aminotransferase; BCKDH, branched-chain-keto-acid dehydrogenase; PC, pyruvate carboxylase; PDH, pyruvate de‐
hydrogenase; KIC, ketoisocaproic acid. Adapted from [21].
Pancreatic β-cells regenerate NAD+ for glycolysis primarily through high expression of
mitochondrial NADH shuttles like glycerol-3-phosphate and the malate/aspartate shuttle (Fig.
3), for specific details refer to [11,22]. Briefly, the glycerol-3-phosphate shuttle consists of
cytosolic and mitochondrial glycerol-3-phosphate dehydrogenase that operate in unison to
convert dihydroxyacetone phosphate to glycerol-3-phosphate and NAD+, with a subsequent
generation of FADH2 from NAD+ [4]. In contrast, the malate/aspartate shuttle is the main
shuttle responsible for transferring glycolytic reducing equivalents to the mitochondria in the
β-cell [11]. Here, cytosolic malate dehydrogenase reduces oxaloacetate to malate and NAD+,
with a subsequent generation of NADH inside the mitochondria. Using an amino group
provided by glutamate, mitochondrial oxaloacetate can be converted back to aspartate
maintaining this cyclic event. The malate/aspartate shuttle is dominantly expressed in β-cells,
eloquently linking glycolysis to mitochondrial & amino acid metabolism.
As alluded to previously, amino acid metabolism is essential for nutrient- and glucose-stimulat‐
ed insulin secretion, and the effects of several amino acids have been reviewed extensively [3,10,
11]. To summarise these findings briefly, both arginine and alanine have been shown to promote
insulin release through changes in electrogenic transport, progressing to activation of Ca2+ ion
channels [10,23,24]. It has also been demonstrated that they enhance glutamate production and
consequently may play a role in malate/aspartate shuttle-mediated generation of NADH, and/or
in glutathione synthesis and antioxidant defence [25]. Therefore, both arginine and alanine may
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protect β-cells from oxidative insult in addition to promoting insulin secretion. However,
prolonged exposure of β-cells to alanine results in decreased alanine-induced insulin secre‐
tion, while reaction of arginine with inducible nitric oxide synthase (iNOS) can promote nitric
oxide (NO) production [10,19]. NO is an important signalling molecule, which is essential for
β-cell glucose uptake at low levels, but at high concentration may be toxic [26]. Interaction of NO
with superoxide (O -) can also lead to the formation of peroxynitrite (ONOO-), a damaging free
radical that can disrupt mitochondrial function [27]. In fact, ONOO-, which is in equilibrium
with its conjugate peroxynitrous acid (ONOOH, pKa ≈ 6.8) [28], is a highly reactive oxidant species
produced by the combination of the oxygen free radical O2- and NO [29] and has been demon‐
strated to be a more potent oxidant and cytotoxic mediator than NO or O2- individually, in a
variety of inflammatory conditions [30]. ONOO- is extremely cytotoxic to rat and human islet
cells in vitro [31] and its in vivo formation has been reported in pancreatic islets where it has been
associated with β-cell destruction and development of T1DM in NOD mice [32].
High levels of homocysteine and cysteine have also been shown to elicit a negative effect on
β-cell function. In obese hyperinsulinaemic T2DM patients, homocysteine levels are increased,
while they are increased in T1DM patients, but only following disease-related complications
Figure 3. The malate–aspartate shuttle is the principal mechanism for the movement of reducing equivalents in the
form of NADH from the cytoplasm to the mitochondrion in β-cells. Cytoplasmic malate dehydrogenase (MDH) reduces
oxaloacetate (OAA) to malate while oxidizing NADH to NAD+. Malate then enters the mitochondrion where the re‐
verse reaction is performed by mitochondrial malate dehydrogenase. Movement of mitochondrial oxaloacetate to the
cytoplasm to maintain this cycle is achieved by transamination to aspartate with the amino group being donated by
glutamate. The 2-oxoglutarate (α-ketoglutarate) generated leaves the mitochondrion for the cytoplasm. Adapted
from [11].
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such as diabetic nephropathy [11,33]. It has been suggested that homocysteine can decrease
GSIS in rat pancreatic β-cells [34], although the inhibitory mechanism is still not fully under‐
stood. It may decrease insulin secretion by altering enzyme and/or protein activity, or by
causing oxidative stress [35,36]. In addition, homocysteine can be converted to asymmetric
dimethylarginine, which is inhibitor of neuronal NOS and can also inhibit iNOS to a lesser
extent and therefore may reduce NO production, which is important for β-cell insulin secretion
and function [10,37]. In contrast, cysteine has been shown to increase β-cell GSIS at low
concentrations [38] and is essential for antioxidant defence and glutathione synthesis, along
with glycine and glutamate. Cysteine supplementation was found to protect β-cells from
hydrogen peroxide (H2O2)-induced cell death and prevented glucotoxicity in mouse β-cells
[39,40]. However, at elevated concentrations, it impaired GSIS through excessive hydrogen
sulphide (H2S) formation [41].
Glutamine is required for β-cell metabolism and function, and is consumed at rapid rates [10].
Glutamine supplementation does not induce insulin release [10], but co-treatment with leucine
significantly enhances GSIS via activation of glutamate dehydrogenase (GDH), allowing entry
of glutamine into the TCA cycle (Fig. 2) [42]. It has been suggested that glutamine alone does
not induce insulin secretion because it is not oxidised during its metabolism. Instead, metab‐
olism of glutamine may yield aspartate and GABA (γ-aminobutyric acid), a potent inhibitor
of glucagon secretion (Fig. 2) [3]. However, using NMR studies, we found that the major
products of glutamine metabolism were aspartate and glutamate. Here, glutamate entered the
γ-glutamyl cycle and increased the synthesis of the antioxidant, glutathione [43]. Formation
of glutamate from glutamine also has important implications in activation of the aspartate/
glutamate shuttles and in ATP production from the TCA cycle, via glutamate metabolism to
α-ketoglutarate. Consequently, glutamine may function to enhance ATP production and
insulin release by changes in down-stream metabolism, most notably via glutamine-derived
glutamate. Alternatively, glutamate can be transported externally from the cell and into the
surrounding matrix, which may cause glutamate receptor activation and desensitisation if the
rate of release is over extended periods [44]. Since glucagon secretion from pancreatic α-cells
is sensitive to glutamate exposure, its release may represent a novel paracrine control mech‐
anism for modulation of blood carbohydrate levels [44]. Some groups have reported that total
intracellular glutamate levels increased in response to glucose, while others reported no
significant change [25,45,46]. Recently, it has been suggested that glutamate is transported into
insulin-containing vesicles, thereby promoting Ca2+-dependent insulin secretion [47]. How‐
ever, the role of glutamate in mediating insulin secretion remains hotly debated.
Taken together, this evidence suggests that a variety of amino acids may contribute signifi‐
cantly to regulation of pancreatic β-cell insulin secretion. However, other β-cell metabolic
processes are important to insulin secretion and must be considered. These include four key
metabolic shunts that divert glucose from being utilised by TCA cycle (i.e., aldose reductase,
pentose-phosphate, glycogen synthesis and hexosamine pathways; please, see Fig. 4) as well
as down-stream glycolytic enzymes such as PC and PDH, and also enzymes involved in fatty
acid metabolism like acetyl CoA carboxylase (ACC) and fatty acid synthase.
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Figure 4. Flux balance analysis of glucose utilisation in β-cells. The fluxes through the biochemical pathways shown
here were calculated by using Michaelis-Menten function, intracellular metabolite concentrations estimated from dif‐
ferent works. Percentages in parentheses refer to the proportional amount of the metabolite consumed through that
step. AR, aldose reductase; ARE, antioxidant response (ARE) elements in the promoter regions of target genes; F6P,
fructose-6-phosphate; G6P, glucose-6-phosphate; G6PDH, glucose-6-phosphate dehydrogenase; G6PI, glucose-6-
phosphate isomerase (a.k. as phosphoglucoisomerase); γ-GCS, glutamate cysteine ligase, a.k. as γ-glutamylcysteine
synthetase; GFAT, glutamine:fructose-6-phosphate amidotransferase a.k. as GFPT, for glutamine-fructose-6-phos‐
phate transaminase; Gluc, glucose; GS, glycogen synthase; GSIS, glucose-stimulated insulin secretion; GSK-3β, glyco‐
gen synthase kinase-3β; HSF-1, heat shock transcription factor-1; HSP70, the 70-kDa family of heat shock proteins
(includes both hsp72, encoded by the HSPA1A gene, and hsp73, a.k. as hsc70, encoded by the HSPA8 gene); Keap1,
Kelch-like ECH-associated protein 1; Nrf2, Nuclear factor erythroid 2-related transcription factor 2; OGT, O-N-acetylglu‐
cosamine transferase, a.k. as UDP-N-acetyl-D-glucosamine:protein-O-β-N-acetyl-D-glucosaminyl transferase and uri‐
dine diphospho-N-acetylglucosamine:polypeptide β-N-acetylglucosaminyl transferase; PFK, phosphofructokinase;
PGmutase, phosphoglucomutase; UGP, UDP-glucose pyrophosphorylase.
Highlighting the peculiarities of β-cell metabolism in a coordinated effort to increase the
activity of a number of metabolic pathways in response to glucose, Huang & Joseph (2012)
have shown, by using metabolomic analysis, during GSIS in clonal β-cells, a conspicuous
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accumulation of pyruvate, succinate, fumarate, malate, α-ketoglutarate, dihydroxyacetone
phosphate (DHAP), (iso)citrate, palmitate, glucose-6-phosphate and 6-phosphogluconate
whereas aspartate was consumed in response to glucose [48]. Here, the authors have clearly
demonstrated that under glucose stimulus, β-cells strongly enhance metabolic flux towards
glycolysis and TCA cycle. Indeed, there is a very delicate poise to coordinately regulate the
flux of glucose towards the formation of NADPH (through the pentose-phosphate shunt)
avoiding excessive formation of sorbitol (via the polyol-aldose reductase shunt) which would
empty glycolytic flux (Fig. 4). It has long been recognised, for instance, that overexpression of
the aldose reductase gene is able to induce apoptosis in pancreatic β-cells by causing a redox
imbalance [49] while, on the contrary, pharmacological blockage of aldose reductase may
impair GSIS, thus suggesting that the conversion of free intracellular glucose to sorbitol in the
β-cell is an essential step in the glucose-induced release mechanism (Fig.4) [50].
Although the physiological significance is still under debate, glucose 6-phosphate may also be
targeted towards glycogen synthesis in pancreatic islets, which is enhanced during GSIS and
impaired in STZ-diabetic rats (Fig. 4) [51,52]. Finally, glucose may be deviated from ultimate
metabolism through further glycolytic steps via the reaction of fructose-6-phosphate with
glutamine through the hexosamine biochemical pathway (HBP) (Fig. 4). Increased fluxes
through HBP may, on the one hand, block glycogen synthase kinase-3β (GSK-3β), thus
liberating glycogen synthesis by glycogen synthase and, on the other, may reduce heat shock
factor-1 (HSF-1) degradation thus allowing enhanced expression of the 70-kDa heat shock
protein (HSP70), which is cytoprotective to β-cells (Fig. 4) [53,54]. Over-enhanced flux through
HBP is an inducer of endoplasmic reticulum (ER) stress, while being associated with insulin-
resistance [55].
PC and PDH are both highly expressed in β-cells and allow conversion of pyruvate to
oxaloacetate (PC) and acetyl-CoA (PDH), with subsequent entry into the TCA cycle [4].
Interestingly, siRNA inhibition of PC reduces cell proliferation and GSIS in insulinoma cells
and rat islets, while overexpression in rat islets could enhance GSIS and cell proliferation [56,
57]. The role of PDH is less understood and it is thought to support PC activity by providing
acetyl-CoA for citrate production. Both enzymes are important regulators of the pyruvate/
malate and pyruvate/citrate shuttles. Common to each pathway is the conversion of glycolytic-
derived pyruvate to oxaloacetate by PC, as described above. In the case of the pyruvate/malate
shuttle, oxaloacetate is then converted to malate and translocated to the cytosol, where malic
enzyme1 (ME1) converts malate back to pyruvate along with generation of NADPH. Pyruvate
can re-enter the mitochondria to repeat the cycle with further generation of NADPH [4].
However, for the pyruvate/citrate shuttle, PC-mediated oxaloacetate leads to condensation
with acetyl CoA (possibly generated by PDH), and the subsequent formation of citrate.
Translocation of citrate to the cytosol results in oxaloacetate and acetyl CoA regeneration from
citrate by ATP-citrate lyase (ACL). Oxaloacetate re-enters the pyruvate/malate cycle with
generation of NADPH as outlined previously, while acetyl CoA is carboxylated to malonyl
CoA by acetyl CoA carboxylase (ACC). Malonyl CoA is then converted to long chain acyl CoA
by fatty acid synthase leading to fatty acid production. Additionally, malonyl CoA can also
inhibit carnitine palmitoyl transferase 1 (CPT-1), which in a low glucose state, transports fatty
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acids into the mitochondria to generate ATP by oxidation [4,10]. However, in high glucose
situations, inhibition of CPT-1 leads to fatty acid accumulation in the cytosol and this accu‐
mulation may increase insulin exocytosis by augmenting calcium influx and ion channel
proteins [10,16]. Interestingly, formation of malonyl CoA from acetyl CoA by ACC is positively
regulated by the glutamine-sensitive protein phosphatase type 2A (PP2A), while it is nega‐
tively regulated by the amino acid-sensitive AMP-activated kinase (AMPK) [11,58,59]. These
concepts again fully illustrate the inherent relationship between β-cell metabolism of glucose,
amino acids and lipids with insulin exocytosis [11,58,59].
AMPK is crucial in lipid metabolism control and can chronically regulate β-cell function by
altering the expression of vital transcription factors that govern lipogenic and glycolytic
enzymes [10]. Chronic exposure of β-cells to high circulatory lipid levels, as occurs in T2DM,
can inhibit glucose oxidation and result in a decreased ATP/AMP ratio along with a subsequent
activation of AMPK, which inhibits fatty acid synthesis, while enhancing fatty acid oxidation,
and impairing GSIS [10]. The exact metabolic mechanisms of how lipids can augment GSIS are
still not fully understood but are believed to involve modulation of Ca2+ mobilisation via
interaction with G-protein coupled receptors [60]. Recent evidence has shown that these G-
protein coupled receptors are highly expressed in β-cells and correlated with insulinogenic
index [10,61]. It has also been demonstrated that interaction of omega-3 fatty acids and the
GPR120 receptor, plays an instrumental role in mediating insulin-sensitisation and anti-
inflammatory effects in obese mice models [62].
AMPK also occupies a central position in metabolic regulation in order to avoid inflammatory
dysregulation. Accordingly, in different cell types, AMPK phosphorylates and inhibit gluta‐
mine:fructose-6-phosphate amidotransferase-1 (GFAT-1), the flux-generating step of HBP
(Fig. 4), thus allowing for the down-regulation of such a shunt from glycolysis under low
glucose situations [63], while chronic hexosamine flux stimulates fatty acid oxidation by
activating AMPK [64]. However, regulatory pathways under AMPK control are not solely
intended to divert metabolic fluxes. Rather, AMPK regulation of GSK-3β allows the concom‐
itant regulation of inflammatory cytokine production, since the inhibition of GSK-3β elicits the
deinhibition of HSF-1, thus triggering the expression of HSP70, which is an intracellular anti-
inflammatory protein.
It is of note that, besides the now classical molecular chaperone action, the most remarkable
intracellular effect of HSP70 is the inhibition of NF- κB activation, which has profound
implications for immunity, inflammation, cell survival and apoptosis. HSP70 blocks nuclear
factor κB (NF—κB) activation at different levels. For instance, HSP70 inhibits the phosphory‐
lation of inhibitor of κB (IκBs), while heat-induced HSP70 protein molecules are able to directly
bind to IκB kinase gamma (IKKγ) thus inhibiting tumor necrosis factor- α (TNFα)-induced
apoptosis [65]. In fact, the supposition that HSP70 might act intracellularly as a suppressor of
NF- κB pathways has been raised after a number of seminal discoveries in which HSP70 was
intentionally induced, such as the inhibition of TNFα-induced activation of phospholipase
A2 in murine fibrosarcoma cells [66], the suppression of astroglial iNOS expression paralleled
by decreased NF— κB activation [67] and the protection of rat hepatocytes from TNFα-induced
apoptosis by treating cells with the nitric oxide (NO)-donor SNAP, which reacts with intra‐
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cellular glutathione molecules generating S-nitrosoglutathione (SNOG) that induces HSP70,
and, consequently, HSP70 expression [68].
HSP70 confers protection against sepsis-related circulatory fatality via inhibition of iNOS
(NOS-2) gene expression in the rostral ventrolateral medulla through the prevention of NF-
κB activation, inhibition of IκB kinase activation and consequent inhibition of IκB degradation
[69]. This is corroborated by the finding that HSP70 assembles with liver NF-κB/IκB complex
in the cytosol thus impeding further transcription of NF-κB-dependent TNF-α and NOS-2
genes that worsen sepsis [70]. This may also be unequivocally demonstrated by treating cells
or tissues with HSP70 antisense oligonucleotides that completely reverse the beneficial NF-
κB-inhibiting effect of HSP70 and inducible HSP70 expression (see [68,69]). Hence, HSP70 is
anti-inflammatory per se, when intracellularly located, which also explains why cyclopente‐
none prostaglandins (cp-PGs), which are the most powerful physiological inducers of HSP70
by activating HSF-1, are at the same time powerful anti-inflammatory autacoids [71-73].
Another striking effect of HSP70 is the inhibition of apoptosis. The intrinsic apoptotic pathway
is characterized by the release of mitochondrial pro-apoptotic factors and activation of caspase
enzymes, while stimulation of cell surface receptors triggers the extrinsic death-pathway. The
inhibitory potential of HSP70 over apoptosis occurs via many intracellular downstream
pathways (e.g. JNK, NF-κB and Akt), which are both directly and indirectly blocked by HSP70,
or through inhibition of mitochondrial Bcl-2 release. Together, these mechanisms are respon‐
sible for HSP70’s anti-apoptotic function in stressed-cells [74].
In conclusion, intracellularly activated HSPs of the 70-kDa family are cytoprotective and anti-
inflammatory by avoiding protein denaturation and excessive NF-κB activation which may
be damaging to the cells [75]. These observations link energy sensing (AMPK) to anti-
inflammation (HSP70) and points out to the complexity of the impact of metabolic regulation
for cell survival and function. In addition, expression of cytokines such as interleukin-1β
(IL-1β), tumour necrosis factorα (TNFα), and interferon-γ (INF-γ) in pancreatic islets is
important in inflammation and progression of both T1 and T2DM, and is associated with β-
cell dysfunction and death. Therefore, agents or nutrients that promote anti-inflammatory
responses may be beneficial as anti-diabetic therapies. Since interaction of the immune system
with pancreatic islets is central to T1DM and is becoming increasing linked to T2DM, the
precise mechanisms of pancreatic cell death in relation to immunological function will now be
discussed.
4. Immune-like characteristics of β-cells and response to cytokines
The pathophysiology of pancreatic islets in T1 and T2DM is characterised by an inflammatory
process that includes immune cell infiltration, presence of apoptotic cells, expression of
cytokines or adipokines and even amyloid deposits [76]. Although the aetiology of T1DM
differs from T2DM, a common feature of both is an immune system-mediated destruction of
pancreatic β-cells, ultimately leading to pancreatic dysfunction and reduced β-cell mass.
However, the immunological-mediated attack does not solely originate from invading
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macrophages and/or cytokines produced by T-lymphocytes, as initially occurs in early stage
T1DM. In fact, it also stems from local production of pro-inflammatory cytokines by the
pancreatic β-cells themselves. The similarity between pancreatic β-cells and immune cells is
an intriguing characteristic. Both can release and respond to cytokines; their function is
dependent on changes in concentration of ROS/RNS and they both express high levels of pro-
inflammatory proteins such as NFκB, iNOS, NOX and TLR’s. Pancreatic β-cells have been
shown to express biologically active cytokines like the pro-inflammatory cytokine IL-1β in
hyperglycaemic conditions [77,78]. Due to their potent effects, cytokine production is strin‐
gently regulated. Control mechanisms include down-stream activation/processing (conver‐
sion of pro-IL-1β to IL-1β by inflammasomes), and co-expression of binding proteins/
antagonists (like the IL-1 receptor antagonist, IL-1Ra), that regulate cytokine bio-reactivity [76].
However, expression of the biologically active form of IL-1β was evident in pancreatic β-cells,
indicating that similar to immune cells, these cells possess the necessary cellular machinery to
allow expression of immunologically active cytokines [77]. Autocrine production of IL-1β, has
been correlated with autoimmune destruction of β-cells in T1DM and is also associated with
glucotoxicity in the pathogenesis of T2DM patients [76,79]. IL-1β elicits its potent cytotoxic
effects through activation of NFκB, and a subsequent initiation of the extrinsic cell-death
pathway [78]. Additionally, chronic exposure to IL-1β results in increased iNOS expression,
and consequently excess NO production. High levels of NO inhibit mitochondrial ATP
synthesis and up-regulate the expression of pro-inflammatory genes in β-cells, which may
potentiate β-cell failure [78].
Similar to macrophages and dendritic cells, β-cells also express TLR’s that normally function
to  regulate  the  immune  system  [80].  TLR’s  interact  with  a  wide  variety  of  pathogen-
related molecules, including lipopolysaccharide (LPS), a component of bacterial cell walls.
This allows phagocytosis of microbes before infection can be established. However, in β-
cells, it is believed that TLR’s play a role in insulin-resistance and inflammation in T2DM.
TLR2 and TLR4 have been suggested as receptors for fatty acids,  and may alter  insulin
signalling during dyslipidaemia. We have shown that β-cells express a range of TLR’s and
could indeed respond to LPS via TLR’s, and this interaction decreased insulin exocytosis
accordingly [80].  However,  glutamine restored insulin release.  Glutamine can also regu‐
late  pro-inflammatory gene expression in  mononuclear  cells  [11,80].  Glutamine also  up-
regulates nuclear factor of activated T cells (NFAT), and thus promotes β-cell growth, while
suppressing β-cell death. Mutations in NFAT-dependent genes have been demonstrated to
result in hereditary forms of T2DM [11]. Moreover, as discussed above, glutamine can enter
HBP thus regulating GSK-3β activity and HSP70 expression which promotes anti-inflamma‐
tion and cytoprotection [53,54].
Pancreatic β-cells are also reported to express other cytokines, including IL-6, IL-8, granulocyte
colony-stimulating factor (G-CSP) and MIP-1 (macrophage inflammatory protein-1) that not
only induce apoptotic β-cell death, but also signal patrolling macrophages, enhancing islet
immune cell infiltration [76]. Macrophages, monocytes, neutrophils and dendritic cells
perform their function by engulfing invading foreign matter including bacteria or dead cells,
and degrade them using super oxide (O2 -) generated from plasma membrane-bound NOX [27].
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β-Cells also express NOX in large quantities, and utilise controlled NOX-derived ROS to drive
mitogenic signalling and proliferation [27]. However, during hyperglycaemia or dyslipidae‐
mia as occurs in T2DM, levels of NOX-derived ROS may increase and overwhelm antioxidant
defences, leading to mitochondrial dysfunction, DNA oxidation, lipid peroxidation and β-cell
death.
These reports illustrate the immune-like characteristics of pancreatic β-cells and clearly
demonstrate the ability of these cells to not only respond to cytokines, but to be capable of
producing endogenous cytokines in an autocrine fashion. This suggests that the immune
system plays an integral part in progression of DM and may offer potential therapeutic targets.
However, to develop immune-related treatments, more research is required into understand‐
ing the mechanisms of islet inflammation in both T1 and T2DM.
5. Islet inflammation in T1DM and T2DM
T1DM is exclusively an autoimmune form of DM, and islet inflammation is characterised by
the presence of leukocyte infiltrates that include B-cells, T-cells, macrophages and Natural
Killer (NK) cells [81]. Macrophages play a critical role since they phagocytose apoptotic and
necrotic β-cells, as well as produce ROS and cytokines (TNFα, INF-γ and IL-1β), that can
promote β-cell death, which leads to patient insulin-dependence. However, effector CD4-
helper and CD8-cytotoxic T-cells represent the predominant pancreatic infiltrate for this
disease, and recent evidence has suggested that T1DM progression may be dependent on a
precarious equilibrium between migration and activation of effector and regulatory T-cells
(Treg) [82]. An important element in T1DM disease development is the generation of autor‐
eactive effector T-cells that kill pancreatic β-cells through expression of Fas, lytic granules and
cytokines such as INF-γ [82]. Research into formation of these autoimmune cell types is still
at an early stage, and it was only definitively shown in 2012, that autoreactive effector
cytotoxic-CD8 T-cells were indeed present in T1DM human pancreatic islets [81]. Furthermore,
the means by which these "homicidal" immune cells are generated and go on to attack β-cells
is still not fully understood. However, part of the process is believed to involve dendritic cell
migration to draining lymph nodes following antigen presentation, and stimulation of
autoreactive T-cell differentiation [82,83]. T-cells sub-sets such as Th1, Th2 and Th17 are thus
formed and they express the necessary weaponry that is responsible for β-cell death in T1DM
[82], this being exacerbated by strong psychological stress [84], one of the possible triggering
factors for the onset of T1DM (for review, please see [85]). Additionally, T-cell–mediated
release of INF-γ and TNFα can up-regulate expression of pro-apoptotic proteins (Bim and
PUMA) leading to β-cell death, along with promoting recruitment and clearance of damaged-
cells by macrophages [77,86]. On the other hand, in normal individuals, activity of these
autoimmune cells is normally controlled by Treg cells and it is the failure to control the action
of effector T-cells that result in autoimmune disease. The mechanisms by which Treg cells
prevent autoimmune attack is also not fully elucidated, but they are thought to prevent
cytotoxic action of T-cells by use of contact inhibition and release of soluble signalling factors,
such as IL-10 and TGFβ (transforming growth factorβ) [82]. It is also unclear whether the
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precise causes of inflammation in T1DM are a consequence of T-cell failure to respond to Treg,
or whether defective or low Treg numbers are to blame for disease progression. Nonetheless,
the interplay between these cell populations offers a potential therapeutic strategy for T1DM
treatment [82].
Interestingly, an autoimmune element has also been reported in patients with T2DM, along
with the accepted thesis of insulin-resistance [76,87]. Hyperglycaemia, dyslipidaemia and low-
grade inflammation (consisting of circulating inflammatory cytokines or adipokines released
by adipocyte expansion), are considered important factors in the progression of T2DM and are
generally present in obese individuals who are at risk of T2DM development [77]. These
conditions lead to β-cell stress through a variety of processes that mainly include uncontrolled
generation of ROS/RNS and cytokine-dependent initiation of death signals. Both processes
combine to reduce β-cell function and decrease β-cell mass by inducing apoptotic cell death,
leading to further hyperglycaemic and dyslipidaemic complications, and causing amplifica‐
tion of ROS/RNS generation, cytokine release and cytokine-mediated recruitment of the
immune system (i.e. inflammation). These inflammatory factors are all detrimental for β-cell
survival. As mentioned previously, IL-1β is elevated in the hyperglycaemic state, is increased
in T1DM and is also expressed by β-cells in T2DM [77-79,88]. Moreover, concomitant down-
regulation of the receptor antagonist IL-1Ra was also observed in β-cells cultured in hyper‐
glycaemic conditions [76]. β-Cells are similar to immune cells and dysregulated expression of
IL-1β in islets can cause auto-stimulation and subsequent release of IL-1β by other β-cells, via
NFκB activation [76,88]. In addition, IL-1β can promote the local expression of other cytokines,
for example IL-6 and IL-8. These cytokines aid in the recruitment of patrolling macrophages,
which may subsequently become activated by high microenvironment levels of IL-1β and
amplify IL-1β content in their own right [76]. In terms of islet inflammation, IL-1β expression
and its effects on β-cell death appears to be a uniting factor, in both T1 and T2DM and is being
considered a possible therapeutic target [77,89].
While inflammation is essential to maintain tissue homeostasis, it is also beneficial and allows
repair of damaged organs. However, it is the presence of chronic, out of control and unchecked
inflammatory factors that contribute to β-cell death and ensuing DM. Ultimately, increased
local microenvironment cytokine production in islets is detrimental and understanding the
mechanisms of cytokine release and regulation, and also suppression of β-cell function, will
allow the development of new treatment regimens.
6. Inflammatory mediators and suppression of β-cell function
Since inflammation and β-cell death is common to both T1 and T2DM, it is reasonable to
assume that shared inflammatory mediators may exist between the two conditions. It is these
mediators that promote infiltration of immune cells, suppression of β-cell function, culminat‐
ing in reduced insulin exocytosis and increased β-cell apoptosis. These mediators can be
loosely classified into four categories, cytokines, chemokines, ROS/RNS and other inflamma‐
tory products. However, it must be noted that the activity of these modulators can be heavily
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influenced by nutrient availability, such as in hyperglycaemia and dyslipidaemia conditions.
Further to this, there is significant crossover between the molecules in these categories, and
several can significantly impact on the others, indicating a complex role in both T1 and T2DM.
T1DM is an autoimmune disease and it comes as no surprise that cytokine expression is
elevated in these patients [79]. Interestingly, it is becoming more evident that cytokines also
play a critical role in T2DM progression, and increased levels have been reported in T2DM
patients [76,87]. The most obvious source of cytokine production is from islet invading immune
cells, although other researchers have illustrated that islet β-cells could also express cytokines
[76,79]. Cytokine and adipokine release also occurs from adipose tissue since it expands rapidly
in obese patients. Here, hypoxia also plays a key part in cytokine release due to an inflamma‐
tory response to lack of vasculature in rapidly growing adipose tissue [90,91]. Recent evidence
has suggested that adipocyte invading macrophages are a significant supplier of TNFα to the
circulation in obese T2DM patients, and this could be a contributing-factor that modulates
inflammation in disease progression [92,93]. It is likely that all sources contribute in some way
or another to elevate cytokine levels, and consequently compound inflammation in DM
patients.
The main cytokines that are responsible for inflammation in T1 and T2DM, include IL-1β,
TNFα, INF-γ, IL-6 and IL-8. Central to the inflammatory role of each is stimulation of stress-
induced kinases, IKKβ (inhibitor of nuclear factor kappaB kinase subunit β) and/or c-JNK (c-
Jun-N-terminal kinase) [90]. Activation of IKKβ leads to translocation and activation of the
NFκB. This factor targets transcription of genes associated with inflammation, and can cause
subsequent up-regulation and release of IL-1β, TNFα, IL-6 and IL-8 [94,95]. Therefore, the
aforementioned cytokines can initiate an auto-stimulatory or feed-forward inflammatory
effect through NFκB-signalling in β-cells, resulting in amplification of inflammation. IL-1β and
TNFα initiate NFκB-signalling directly via association with their relative receptors (IL-1R and
TNFR) [96] and can also activate the apoptotic JNK pathway indirectly by intracellular
interaction of TNF receptor associated factor (TRAF) with the cytoplasmic portion of IL-1R or
TNFR [97]. NFκB can play either a pro-survival or pro-death role given the correct circum‐
stances [98]. Both NFκB and JNK are intrinsically connected, and NFκB can prevent JNK-
mediated cell death, the regulatory interactions of which have been reviewed expertly
elsewhere [99]. An important component of NFκB activation and function is the presence/
absence of ROS/RNS. Therefore, ROS/RNS can influence NFκB-dependent cytokine expression
and consequently immune response [98].
ROS/RNS can activate nuclear translocation of NFκB which promotes gene expression.
However, ROS/RNS can also have an inhibitory effect when NFκB has already translocated to
the nucleus [98]. The process by which ROS/RNS affects NFκB function is not entirely known
but is believed to involve alteration of the NFκB catalytic site through interaction with cysteine
residues, or by inhibiting specific kinase enzymes such as IκBα, that results in phosphorylation
of NFκB [98]. Cellular ROS can be generated from Electron Transport Chain (ETC) respiratory
complexes or from specific enzymes (e.g. NOX-mediated production for phagocytosis) [27,98].
Most notably, in hyperglycaemic/glucotoxic conditions (in T1 or T2DM), mitochondria are the
major source of ROS/RNS primarily because of high oxidative phosphorylation and ATP
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production [100]. As a result of unavoidable oxidative chemistry and prolonged ETC activity,
superoxide (O2 -) anions can be formed and may “leak” from the mitochondria and elicit cellular
damage [100]. Additionally, excess glucose can cause increased intracellular calcium, which
may enhance mitochondrial O2 - output, but also activate NOX-derived ROS via protein kinase
C (PKC) [100]. High glucose can also induce NOX activity through NADPH production from
the conversion of glucose-6-phosphate to pentose leading to increased O2 - [100]. Superoxide
is a precursor reactive species and can be converted to other forms of strong oxidants including
H2O2, and free radicals such as hydroxyl radicals and also peroxynitrite following reaction
with NO [27,100]. These reactive species can cause DNA, lipid and protein damage and can
also activate/regulate NFκB, who in turn can promote cytokine release and increased NO/O2 -
production by activation of iNOS and NOX expression [100,101]. Thus, ROS/RNS can exacer‐
bate the immunological response and lead to cell death in a cyclic fashion (Fig. 5).
Lipid- and adipose-derived factors are considered other inflammatory mediators. In T2DM
patients, dyslipidaemia occurs along with hyperglycaemia and consequently vascular
circulation and intracellular accumulation of lipids can have a profound effect on the inflam‐
matory response. Excess fatty acids can induced ROS generation through increased TCA
metabolite production, increased NADH/NAD+ ratio and elevated intracellular Ca2+ [100].
They can also increase O2 - and NO production via activation of NOX and iNOS, respectively,
all potentially activating the NFκB pathway [97,100,102]. Formation of ceramide from long
chain fatty acids also contributes to precipitation of lipotoxicity in β-cells and results in ROS
generation and apoptotic death [97,100]. Ceramide, synthesised by serine palmitoyltransferase
from long chain fatty acids like palmitic acid [100], is capable of inhibiting the pro-survival
PI3K pathway, activating caspase-9 [100]. Like other fatty acids, ceramide can associate with
and activate TLR’s, which may elicit an immune response [90].
Since adipose tissue expands in obese patients, increased adipose-derived factors have been
detected in patient serum, including leptin, TNFα and IL-6. Leptin and adiponectin can play
a role in the immune reaction in DM patients. Leptin, an appetite control endocrine factor,
inhibits feeding by interaction with receptors in the hypothalamus and a subsequent stimu‐
lation of neurotransmitter release, for example norepinephrine [103]. It is considered a cytokine
due to its homology in structure with IL-6, and its receptor-mediated effects [77,103,104]. It
has been shown to induce β-cell death by up-regulating IL-1β, and has also been implicated
in exacerbation of T1DM in animal models [77,105]. Conversely, adiponectin is considered an
anti-inflammatory protein, and enhances IL-1Ra and IL-10 expression [90,106], leading to
reduced IL-1β and enhanced suppression of T-cell mediated inflammation.
Chemokines can also be secreted from adipose tissue and are elevated in the adipose tissue of
obese mice and humans [90,107]. CC-chemokine ligand-2 (CCL-2) functions to recruit mono‐
cytes to adipose tissue resulting in differentiation into activated macrophages [108]. Others such
as CCL-3, CCL-6, CCL-7, CCL-8 and CCL-9, have also been reported to be elevated in high-fat
fed mice, suggesting they may play a role in immune cell recruitment and inflammation [90].
Several mechanisms and modulators may contribute to the inflammatory response observed
in T1 and T2DM. Cytokines, ROS and NFκB-signalling appear to be critical in mediating
immune cell infiltration and further cytokine production. The balance between β-cell survival
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Figure 5. Illustration depicting the potential convergence points of the immunological NFκB and the metabolic
ROS/ER stress pathways in pancreatic β-cells. Islet inflammation is characterised by the presence of leukocyte infil‐
trates that mediate the destruction of β-cells by release of cytokines, generation of ROS (NO, cytokine-NFκB-depend‐
ent]) and by activating the granzyme b- and death-receptor-mediated death pathways. Also shown is the effect of
excess glucose on ROS production and ER stress that ultimately activates caspase enzymes via mitochondrial- and ER-
mediated death pathways. ROS/RNS can also activate and regulate the NFκB stress pathway, which may lead to ex‐
pression of cytokines that promotes immune cell infiltration exacerbating β-cell death.
The Impact of Inflammation on Pancreatic β-Cell Metabolism, Function and Failure in T1DM and T2DM…
http://dx.doi.org/10.5772/55349
143
and death is dependent on the interactions of these mediators, but also on the glycaemic and
lipidaemic environment. We will now discuss the precise mechanisms of β-cell death in T1
and T2DM, and examine the commonalities between both.
7. Pancreatic β-cell failure and death in T1DM
Pancreatic β-cell failure can be defined as a reduction in insulin secretion or a failure to respond
to plasma glucose (i.e. insulin-resistance). β-cell dysfunction in T1DM is characterised by an
autoimmune-mediated destruction of β-cells leading to a decrease in pancreatic β-cell mass
and reduced insulin secretion [109]. On the other hand, progression of T2DM is more variable
and β-cell death occurs against the backdrop of insulin-resistance [109]. Here, the pathogenesis
of T2DM usually involves a response to increased metabolic load by increased β-cell mass and
enhanced insulin secretion [110]. A period of normoglycaemia ensues before a reduction in
insulin secretion and β-cell function is observed. Finally, this phase is followed by a decrease
in β-cell mass due to apoptotic cell death and is referred to as overt diabetes [110,111]. The
shared feature associated with both T1 and T2DM is the failure of pancreatic β-cells resulting
in reduced cell mass, dysfunction and ultimately apoptotic death. While there are common‐
alities associated with both types, the main mechanism of cell death associated with T1DM is
immune-related.
At the time of diagnosis, T1DM patients present with a 70-80% reduction β-cell mass [109].
Insulitis and infiltration of leukocytes into islets is common in these patients. Several types of
leukocytes are present including B-cells, macrophages and Natural Killer (NK) cells, but the
principal invading cell type is the cytotoxic T-cell (CD4 and CD8) [81,82]. Immune cells
promote β-cell death via several mechanisms, and these can be simplified to include phago‐
cytosis, production of cytokines and T-cell-induced initiation of death-receptor-mediated
apoptosis. The intracellular generation of ROS/RNS and activation of caspase enzymes occurs
inside target cells and ultimately seals the fate of these cells.
Generation of autoreactive effector T-cells is extremely important in the pathogenesis of T1DM,
but the precise biochemical mechanisms behind release of self-antigen and development of
autoreactive T-cells remains unknown. However, work in this field has identified a potential
role for decreased expression of peripheral tissue antigens (PTA) in pancreatic draining lymph
nodes, which possibly allows unchallenged escape of differentiated autoreactive T-cells
[82,83,112]. These T-cells kill pancreatic β-cells through expression of Fas ligand and expres‐
sion of extracellular cytotoxic factors including cytokines, and lytic granules containing
granzyme B and perforin [113]. In death-receptor-mediated apoptosis, Fas ligand or TNFα
initiates death signals through association with FasR (Fas receptor) or TNFR (tumour necrosis
factor receptor). An intracellular conformational change occurs that results in activation of
caspase-8 [114,115]. This in turn serves to activate caspase-3 downstream promoting the
apoptotic cascade [116].
T-cell-mediated release of granzyme B and perforin also leads to caspase activation in target
cells. Here, perforin creates pores in the plasma membrane of the target cell, while granzyme
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B is released into the cytosol and activates caspase-3 [113,117]. Interestingly, in order to yield
activation of caspase-3, both caspase-8 from the death-receptor pathway outlined above, and
granzyme B converge and initiate the mitochondrial-mediated death pathway via cleavage of
BID [a member of the B-cell lymphoma-2 (Bcl-2) family of proteins], to truncated BID (tBID).
In this process, cytosolic tBID translocates to the mitochondrial membrane and activates other
Bcl-2-related proteins, such as BAX. Release of cytochrome c is then stimulated, which acts as
the trigger for mitochondrial-mediated activation of caspase -9 and -3 [118,119,120]. Therefore,
both the death-receptor and granzyme B-mediated death pathways activate the mitochondrial-
mediated death pathway.
Conversely, macrophages induce β-cell death through production of ROS, cytokines and
eventually phagocytosis. Macrophages express high levels of NOX, and use O2 - to kill invading
organisms or possibly damaged β-cells. Expression of high amounts of ROS/RNS or reduced
antioxidant defences, results in mitochondrial dysfunction, which can culminate in mitochon‐
drial-mediated apoptosis. Briefly, this involves major structural changes caused by ROS/RNS-
mediated lipid/protein oxidation on both the inner and outer mitochondrial membranes, thus
increasing the membrane permeability to proteins [121]. This is regulated by the interaction
of pro- and anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-XL, BAX, BAK, BIM, BID and BAD)
[122]. The release of cytochrome c to the cytosol and its association with apoptosis protease
activation factor-1 (Apaf-1) and pro-caspase-9, forms a heptameric wheel-like caspase-
activating complex, known as the apoptosome, which subsequently leads to activation of
caspase-9 and effector caspase-3, further down-stream [123]. Caspase activation promotes cell
death by degradation of DNA and cytoskeletal proteins [124].
In addition, immune cells release cytokines (e.g. TNFα, INF-γ and IL-1β) that also promote
up-regulation of ROS/RNS via activation of NFκB (e.g. NO), who in turn can be regulated by
ROS [100,101]. Induction of NO expression can cause activation of tumour suppressor protein
(p53) leading to inhibition of cell cycle and death [109]. Cytokines can also inflict cell death via
stimulation of the JNK pathway [97]. Here, IL-1β and TNFα activate mitochondrial translo‐
cation of JNK, who is a regulator of Bcl-2 proteins. JNK phosphorylates BIM, which results in
the release of BAX-dependent cytochrome c and initiation of mitochondrial-mediated apop‐
tosis [125,126]. Additionally, release of INF-γ by T-cells, can also phosphorylate BIM in β-cells,
promoting cell death in a similar manner [77,86].
A variety of biochemical signalling pathways are available by which autoimmune cells utilise
to initiate β-cell destruction. Consequently, due to a complete lack of insulin secretion and
subsequent diminished glucose-uptake by muscle and adipose tissue, hyperglycaemia ensues
in T1DM patients. High levels of blood glucose leads to further complications including,
glucotoxicity, lipotoxicity and glucolipotoxicity and these are key players in exacerbation of
the disease, and can lead to the clinical complications of T2DM [108]. Therefore, the precise
way in which these factors affect β-cell turnover and survival will be discussed in the next
section. Nonetheless, β-cell death in T1DM is based on classical immune-related death
processes, but also relies on involvement of ROS and mitochondrial mediated which may occur
in a sub-population of beta cells in T2DM.
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8. Pancreatic β-cell failure and death in T2DM
Failure of pancreatic β-cells is essential in the progression of both T1 and T2DM. The devel‐
opment of T2DM is more gradual than T1, and appears to occur in specific stages. It is
dependent on the establishment of insulin-resistance and displays increased degrees of
variability in comparison with T1DM. Therefore, determination of the precise mechanisms of
T2DM-related cell death remains difficult and, these are still not fully understood.
T2DM patients have a 30-50% reduction in β-cell mass on average post-mortem and the
primary candidate pathways leading to β-cell apoptosis are oxidative stress, ER stress, amyloid
accumulation, ectopic lipid deposition, lipotoxicity and glucotoxicity [127]. These stresses can
all be caused by over-nutrition and neatly connects T2DM to obesity [90]. Glucose, the most
important insulin secretatogue, is also the most important regulator of β-cell mass and function
[128]. Impaired glucose-tolerance and hyperglycaemia are hallmarks of T2DM and prolonged
glucose exposure can promote glucose-desensitisation, decreased insulin secretion and
generation of oxidative stress in β-cells [128]. Consequently, glucotoxicity plays a significant
part in pancreatic β-cell death in T2DM.
Understandably, excess glucose increases β-cell glucose metabolism and oxidative phosphor‐
ylation. Elevated ETC activity promotes increased superoxide (O2 -) anion leakage from the
mitochondria and may cause oxidative cellular damage [100]. Furthermore, high glucose levels
induces NOX activity via NADPH production from metabolism of glucose to pentose, and
through the TCA cycle, both leading to increased O2 - output [100]. O2 - can be converted to the
less reactive H2O2 via superoxide dismutase, to the highly reactive hydroxyl anion by the iron-
catalysed Fenton reaction, or to peroxynitrite (ONOO-) via reaction with iNOS-derived NO
[27,129]. β-cells are considered vulnerable to ROS/RNS generation because they express
relatively low levels of antioxidant enzymes, like glutathione and catalase [27,128,129]. These
enzymes immediately convert H2O2 to molecular oxygen and water. However, the detrimental
combination of reduced activity of antioxidant enzymes, along with ROS/RNS generation can
result in oxidative damage to DNA, lipids and proteins, thereby promoting mitochondrial-
mediated apoptosis. In addition, ROS/RNS can also activate and regulate biochemical stress
pathways, such as the NFκB, leading to further negative effects in β-cells [100,101].
Excess glucose can cause increased intracellular calcium, as outlined previously, which may
enhance mitochondrial O2  -  production, but also deplete ER Ca2+,  promoting activation of
the ER-stress-mediated death pathway [111,128] alongside unfolded protein response (UPR)
(for review, please see [130]). In normal conditions, proteins are synthesised in the ER and
are subsequently secreted or routed into a variety of sub-cellular compartments. Howev‐
er, accumulation of native or unfolded proteins within the lumen of the ER can activate
caspase enzymes and ultimately promote cell death [131,132]. Reaction of ROS with the ER
leads to protein accumulation via dysregulation of the ER oxidative folding pathway [111].
It also results in oxidative activation of Ca2+ release channels in the ER membrane, thereby
depleting  the  ER  of  Ca2+  [111].  This  ER  stress  activates  pro-caspase-12,  located  on  the
cytoplasmic side of the ER, in a manner similar to caspase-9 [133,134]. Caspase-12 apopto‐
somes  also  causes  translocation  of  JNK  to  the  mitochondrial  membrane  inducing  BIM
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phosphorylation, ultimately leading to cytochrome c release and initiation of mitochondrial-
dependent apoptosis [111,135,136].
Lipid accumulation (lipotoxicity) in the ER may also play a significant function in mediating
ER stress in β-cells. Obesity is a primary risk factor associated with T2DM, and is accompanied
with increased plasma glucose and lipid levels due to high carbohydrate- and fat-based diets
[137]. The process by which free fatty acids modulate ER stress is not entirely known [111] but,
it has been shown that palmitic acid could deplete ER Ca2+ levels and augment ER morphology
and integrity, which may cause activation of ER stress by the mechanisms mentioned above
[137,138]. Furthermore, excess fatty acid esterification in the ER, may divert ER machinery and
delay the processing and export of proteins in the ER [137]. Since there is a large demand for
protein/insulin production in pancreatic islets, β-cells have a highly active and well developed
ER. This suggests that β-cells may be more susceptible to ER stress during protein synthesis
[109,137]. Given the effects of elevated plasma glucose and lipids in T2DM patients, ER stress
could be a vital mechanism facilitating glucotoxicity-, lipotoxicity- or glucolipotoxicity-
mediated β-cell failure and death [137].
Moreover, accumulation of islet amyloid polypeptide (IAPP) may also contribute to β-cell
dysfunction and death in a manner similar to that described above [110,111,139]. IAPP
precipitates into lethal oligomers inside the ER and like unfolded proteins, activates the ER
stress-mediated death pathway [139]. IAPP deposits are present in over 90% of T2DM islets,
post-mortem, indicating a substantial participation in T2DM progression [109,111].
In summary, several biochemical mechanisms have been suggested to be responsible for
pancreatic β-cell failure and death in T2DM. However, there appears to be significant interplay
between the purported pathways and conditions of glucotoxicity-, lipotoxicity- and glucoli‐
potoxicity, which are common in the aetiology of T2DM and require further investigation.
Interestingly, from this review there are noteworthy commonalities associated with T1 and
T2DM mechanisms of β-cell failure and death. In the following section we will attempt to
summarise these, with a view to identifying the potential therapeutic targets that are of interest
to the research community.
9. Similarities between β-cell failure and death in T1DM and T2DM
T1DM is considered a chronic autoimmune disease and the major mechanisms responsible β-
cell death and dysfunction are immune-related. In contrast, the main mechanisms responsible
β-cell death and dysfunction in T2DM are related to metabolism. Thus, the convergence points
of these two aetiologically-different disorders appear to be the immunological NFκB pathway
and, the metabolic ROS/ER stress pathways (Fig. 5).
Islet inflammation in T1DM is characterised by the presence of leukocyte infiltrates [81]. In
particular, macrophages and T-cells mediate the destruction of β-cells by phagocytosis, release
of cytokines, generating ROS (NO, cytokine-NFκB-dependent [82]) and by activating the
granzyme b- and death-receptor-mediated death pathways (Fig. 5). At the biochemical level,
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production of cytokines such as INF-γ, TNFα and IL-1β act in synergy to promote expression
of iNOS and consequently NO, via stimulation of NFκB in mouse islet β-cells [82]. If not
regulated, this generation of ROS may impact on ER stress and possibly promote cell death,
which has been shown to be an import cell death process in T2DM (Fig. 5). Furthermore,
cytokine–mediated activation of β-cell NFκB may result in an autocrine production of similar
cytokines by β-cells, amplifying these death signals [76,79]. Another complication that arises
with T1DM and immune-mediated reduction of β-cell mass is impaired insulin secretion,
which may possibly promote additional hyperglycaemia and dyslipidaemia in these patients.
Therefore, and as explained earlier, glucolipotoxicity may follow, along with further cell death
that is achieved through mitochondrial- and/or ER-mediated death processes (Fig. 5).
In T2DM, hyperglycaemia and dyslipidaemia are critical factors and are generally present
in obese individuals with the disease [77]. Consequently, excess glucose and circulating free
fatty acids may promote increased ROS production and ER stress by enhancing oxidative
phosphorylation and causing a build-up of unfolded proteins in the ER. Elevated ROS and
ER stress will activate caspase enzymes via mitochondrial- and ER-mediated death path‐
ways, respectively (Fig. 5). Interestingly, ROS/RNS can also activate and regulate the NFκB
stress pathway, which may possibly lead to transcription of genes coding either cytokines
or immune cell chemo-attractants (Fig. 5) [98]. Given the spontaneous reactivity of ROS, it
is not clear yet exactly how it influences NFκB activation. However, it has been shown to
react in a variety of ways promoting stimulation or inhibition of NFκB, with effects depend‐
ent on context [98]. For example, if ROS does promote expression of NFκB-derived cyto‐
kines or immune cell chemo-attractants, these signals may alert nearby macrophages and T-
cells to the elevated level of β-cell ROS, and initiate the removal of these damaged cells.
Consequently, this could result in immune cell infiltration into pancreatic islets of T2DM
patients and possibly β-cell death (Fig. 5).
Interestingly, an autoimmune element has been reported in obese patients with T2DM, who
have presented with elevated circulatory cytokine and acute-phase protein levels [77,87]. A
common denominator that may link both T1 and T2DM is IL-1β. Autocrine production of
IL-1β by β-cells has been observed in T1DM and in T2DM patients [76,79]. Furthermore, in
vitro culture of islets from non-diabetic doners in high glucose, caused increased production
and secretion of IL-1β, along with subsequent NFκB activation, Fas up-regulation, reduced
insulin secretion and β-cell DNA fragmentation [77,78]. Chronic exposure to IL-1β also
increases expression of iNOS, and consequently may up-regulate ROS generation and the
expression of other pro-inflammatory cytokines like IL-6 and IL-8, which may further poten‐
tiate β-cell failure [78]. These reports clearly demonstrate the inherent link between glucotox‐
icity and the inflammatory processes [77]. In addition, investigators took a step further and
showed that exogenous addition of IL-1Ra, the IL-1 receptor antagonist (Anakinra), protected
the islets from IL-1β, but also reduced glycated haemoglobin in a small clinical trial of T2DM
patients [77,140]. Clinical trials utilising IL-1Ra, still continue [90].
In conclusion, T1 and T2DM are different diseases, but do appear to share some common
biochemical ground in terms of disease development. Although T1DM is mostly an autoim‐
mune-related syndrome, elements of metabolic dysregulation are evident. Likewise, even
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though T2DM is very much a metabolic disease, there are also immunological-related factors
that may exacerbate disease progression. NFκB, IL-1β, ER-stress and generation of ROS/RNS
are instrumental players in both diseases, and may warrant further investigation with regard
to development of novel therapies.
10. β-cell therapies and possible targets for prevention of β-cell failure
The traditionalistic concept of separate T1 and T2DM syndromes has become clouded with
knowledge of the involvement of inflammation in T2DM and the metabolic syndrome in T1DM
[108]. It is now apparent that treatment modalities that were specifically designed for one form
of diabetes may have application in the other. Exercise, weight loss and diet are the most
effective strategies to delay T2DM disease development, but similar strategies have shown
significant efficacy in T1DM [108,128].
Researchers have targeted TNFα in children with newly diagnosed T1DM and showed that a
recombinant TNFR fusion protein preserved c-peptide function, along with enhancing insulin
production [82,141]. However, to date, anti-TNFα treatment has failed to improve blood
glucose in T2DM patients [90]. Infiltration of cytotoxic T-cells in T1DM has been well charac‐
terised [82]. Therefore, some developing treatment strategies for this precise component of
T1DM disease is the generation of T-cell targeted therapy to prevent the destruction of
transplanted islets, some of which include introduction of anti-inflammatory Tregs that
regulate T-cell activation [89]. Since inflammation has been detected in T2DM, these ap‐
proaches may have similar applications. Directing treatment towards the immunological
pathways is quite attractive and recent evidence has suggested that the most promising results
involve blockade of IL-1β or NFκB activation [90]. Again, it is noteworthy to highlight that
enhanced HSP70 expression has been convincingly demonstrated to protect against obesity-
induced insulin-resistance [142], while low HSP70 contents in skeletal muscle of T2DM
patients are associated with insulin-resistance [143,144]. Hence, pharmacological (e.g. the
hydroxylamine derivative BGP-15, now under clinical trial) as well as physiological (hyper‐
thermic, hot tube) treatments have started to be cogitated as promising therapeutic approaches
in T2DM [142,145]. Moreover, physical exercise, which is a powerful antidiabetic intervention,
is one of the strongest ways to increase intracellular HSP70 expression in many tissues (for
reviews, please see [75,146]), including in pancreatic β-cells (A. Bittencourt et al., manuscript
in preparation).
Elevated IL-1β and reduced IL-1Ra is known to correlate with T1DM, but the recent identifi‐
cation of inflammation in T2DM has meant that the IL-1 receptor antagonist (Anakinra), has
been trialed in both T2DM and T1DM patients with successful results [77,140,147]. Here, the
agent lowered blood glucose, reduced inflammation, improved insulin-sensitivity and
secretion. These reports again illustrate the pivotal role played by IL-1β in mediating DM
development, and thus clinical trials continue [90].
Salicylate-derivatives, such as salsalate, are also being used in an anti-inflammatory capacity
to inhibit the activation of NFκB, although the precise mechanisms of action are not fully
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understood. These agents have the clear advantages of being orally available and well
tolerated. Salsalate has been shown to improve insulin sensitivity and production, increase
secretion of the anti-inflammatory cytokine adiponectin, reduce blood glucose and C-reactive
protein (CRP) and decrease fatty acid and triglyceride levels [90].
From our own studies we have shown how different amino and fatty acid combinations may
affect β-cell metabolism. This proposes the concept of diet manipulation as an additional
treatment for hyperglycaemia and lipidaemia in T2 and even T1DM patients. We demonstrat‐
ed the antioxidant activities of arachidonic acid, arginine and glutamine, and this data may
suggests that dietary supplementation, high in specific amino or fatty acids, may have
favourable effects in DM patients. Given the role of ROS and ER stress in β-cell death, dietary
or pharmacological agents that target these pathways may also represent novel treatments for
the delay or prevention of DM.
11. Conclusions and perspectives
Over-nutrition and diminished physical activity in the modern lifestyle has led to a staggering
increase in T2DM onset in Western cultures [108]. However, the epidemic is also progressing
into the developing world, indicating that T2DM has become a major global health issue [108].
Since the 1990’s, T1DM has more than doubled in number and is expected to double again
before 2020 [108,148]. The traditional classification of distinct criteria for T1 and T2DM
syndromes has become blurred due to the global increase in obese individuals and the
incidence of obesity-related insulin-resistance [108]. Currently the paradigm of T1 and T2DM
treatment appears to be changing in line with the clarification of dysfunctional pathways that
are common to both disease types. Although diet-and-exercise still remains the most effective
(and cheapest) treatment, new therapies will be required going into the future. Consequently,
an increased understanding of the molecular and biochemical mechanisms that lead to disease
onset and progression are mandatory.
In this manuscript, we have examined some of the key pathways that are essential in the
pathogenesis of both T1 and T2DM, and we have reviewed some of the novel treatments that
are currently being developed to counteract these dysfunctional processes. It is clear that
inflammation, generation of ROS/RNS and ER stress leads to significant damage to pancreatic
β-cells, culminating in cell dysfunction, and ultimately cell death. It is hoped that further study
of the NFκB and the ER stress-mediated pathways, will reveal novel therapeutic targets that
can be developed into a new generation of anti-diabetic treatments, that will improve β-cell
function, survival and regeneration in T1 and T2DM.
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